InsightRX

InsightRX provides software that helps clinicians optimize dosing regimens, reach clinical targets faster, reduce adverse events, and improve patient outcomes.

[InsightRX @InsightRX]

A new study concludes that the Bayesian adaptive dosing strategy significantly improves the accuracy of achieving the target busulfan AUC in patients undergoing HCT.

Published in British Journal of Clinical Pharmacology.

https://t.co/b2cgPoxQic | #Bayesian #AUC #HCT #Busulfan

[InsightRX @InsightRX]

Happy New Year! The InsightRX Team wishes you a safe and happy 2025! | #HappyNewYear #Happy2025

[InsightRX @InsightRX]

This recent study addresses the question, can we extract unrecognized #SADRs with known #PK mechanisms from biomedical literature using natural language processing tools & validate DDIs-SADR signals through multi-source EHR databases?

https://t.co/a9E2pJhJA5 | @ASCPT_ClinPharm

[InsightRX @InsightRX]

A new study evaluates whether the pediatric selexipag dosage recommendation, based on the #PopPK model for adults, achieves similar drug exposures in #PediatricPulmonaryArterialHypertension (PAH) patients: https://t.co/F9btWGl5Dr

[InsightRX @InsightRX]

Wishing you a safe and happy holiday season from the InsightRX Team! #HappyHolidays #OurTeamToYours

[InsightRX @InsightRX]

A new study examines the link between #vancomycin supratherapeutic dosing & #AKI using a novel correlation factor equation.

Key finding: All AKIs occurred with AUC <600—pharmacists should assess other AKI causes.

Author: Yazan Batarseh, @HMCHospital:
https://t.co/yzMI3htK0M

[InsightRX @InsightRX]

The goal of this study was to leverage ensemble learning approaches to develop physiological aging measures from point-of-care #biomarkers.

Published in Pharmacometrics & Systems Pharmacology.

➡ https://t.co/SCw8HS4Db2 | #PhysiologicalAge #PrecisionMedicine #PrecisionDosing

[InsightRX @InsightRX]

In this editorial, scientists call upon the #ClinicalPharmacology & translational science community to collaborate across sectors & disciplines to be able to collectively transform the landscape of rare & neglected diseases.

https://t.co/MnGaSs7bfx #RareDisease #ClinicalResearch

[InsightRX @InsightRX]

In this episode of the Oncology Unplugged series, @CParkMD, @Norton Healthcare Cancer Institute, hosted a conversation with @VivekSubbiah, @SarahCannonDocs.

Learn more via @OncLive: https://t.co/fOWFKpxqCi | #PrecisionMedicine #PrecisionOncology @MJHLifeSciences

[InsightRX @InsightRX]

A new study demonstrates that the selection of an appropriate adult reference population is important for pediatric PK exposure matching & pediatric dose selection, especially for a drug substantially eliminated through renal excretion: https://t.co/755KhZf3y3 | #Pharmacokinetics

[InsightRX @InsightRX]

A new study concluded that following the implementation of a pharmacist-driven #AUCMonitoring program, patients were less likely to develop nephrotoxicity during outpatient #vancomycin therapy.

https://t.co/vRknH4Xm64 | #PrecisionMedicine #AntimicrobialTherapy @BrighamWomens

[Pharmacotherapy @PharmacoJournal]

Over 380K vancomycin treatment courses were used to evaluate the predictive performance of various vancomycin PK models across diverse age and BMI categories. Learn how to apply these findings to your patient. https://t.co/L6KMmeP8CJ @InsightRX @Steph_lnfection @idpharmresearch

[InsightRX @InsightRX]

A new study aimed to identify the optimal PK/PD predictor and assess the correlation between AUC/MIC, trough concentration and the vancomycin efficacy in neonates.

https://t.co/tc5FLyj1lc | #PrecisionMedicine #Vancomycin #Pharmacokinetics #Pharmacodynamics #PKPD

[InsightRX @InsightRX]

Stephanie Hughes, PharmD, BCIDP, joins Dr. Michael Rybak on the @ACCP Journal Podcast to discuss her study on #vancomycin #PKModels in diverse age & BMI groups.

Learn how to apply insights from 380K+ treatment courses to your patients.

🎧 Listen now: https://t.co/TU2ZCSJ51e

[InsightRX @InsightRX]

We’re pleased to announce that we will be presenting a research abstract at the @ASHPOfficial 2024 Midyear Clinical Meeting on Dec. 8-12 in New Orleans.

Learn more: https://t.co/Edka3dTPeY | #PrecisionMedicine #PrecisionDosing #CockcroftGaultEquation #PKPD #TherapeuticDosage

[InsightRX @InsightRX]

This study compares GFR models to the Mech-KiM model with hypothetical drugs and metronidazole (96% reabsorption).

Dive into the findings in CPT: Pharmacometrics & Systems Pharmacology: https://t.co/z33cbWQYxr

#Pharmacometrics #Pharmacology #Pharmacokinetics #PBPK

[InsightRX @InsightRX]

The InsightRX Team would like to wish you a safe and Happy Thanksgiving! We are grateful for all the clinicians working today and every day to keep their patients safe.
#HappyThanksgiving #Grateful #Thankful

[InsightRX @InsightRX]

This recent study investigated which factors are associated with receiving pharmacogenetically targeted drugs & estimated cost-effects of untargeted pre-emptive #pharmacogenetic panel testing with #CostBenefitModel. https://t.co/6MfMofL1UL @UniTurku @helsinkiuni @ASCPT_ClinPharm

[InsightRX @InsightRX]

A new study concludes that the combined CKD-EPICR-CYS performs best in terms of predicting pharmacokinetics of pemetrexed.

Published in Cancer Chemotherapy and Pharmacology.

https://t.co/YRg2xNSbA7 | #Pharmacology #Pharmacokinetics #PrecisionMedicine #OncologyTreatments

[InsightRX @InsightRX]

@NIPERHyd @ASCPT_ClinPharm

[InsightRX @InsightRX]

A new study addresses if a #PBPK model coupled with a relative transcriptomics approach can predict local anifrolumab tissue concentrations & receptor occupancy, to guide dose selection for phase III anifrolumab studies in new indications: https://t.co/4DC7e2sGzB